CTOs on the Move

Aledade

www.aledade.com

 
Aledade is a new company with an old-fashioned goal: putting doctors back in control of health care. Aledade partners with independent, primary care physicians to provide everything the doctors need to create and run an Accountable Care Organization (ACO) – from business and practice transformation services to upfront capital and a cutting-edge technology platform. Our customized solutions – and our continuous, on-the-ground support of our physician partners – will help doctors in all types of communities across America preserve their autonomy, deliver better care to their patients, reduce overall costs, and keep independent physician practices flourishing.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.aledade.com
  • 4550 Montgomery Ave Suite 950
    Bethesda, MD USA 20814
  • Phone: 202.803.7979

Executives

Name Title Contact Details
Jonas Goldstein
 Senior VP, Transformation Profile
Ritwik Tewari
 Chief Technology Officer Profile
Tyson Kopczynski
 Chief Information Security Officer Profile
Kallie Smith
 Director Information Security Profile
Eric Banks
 Chief Information Security Officer Profile

Funding

Aledade raised $30M on 06/15/2015
Aledade raised $20M on 01/11/2017
Aledade raised $23M on 12/19/2017
Aledade raised $46.1M on 10/17/2018
Aledade raised $10M on 01/19/2019
Aledade raised $64M on 04/20/2020
Aledade raised $100M on 01/19/2021
Aledade raised $123M on 06/06/2022

Similar Companies

Saskatchewan Research Council

Saskatchewan Research Council is a Saskatoon, SK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amarantus

Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The Company has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia and Adult ADHD. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders.   Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard").

Celladon

Celladon is a privately held biotechnology company founded with the goal of developing molecular therapies for cardiovascular diseases. Breakthroughs in the basic understanding of the cardiovascular networks combined with powerful new technologies have provided the foundation for new, rational, and technologically sophisticated approaches to cardiovascular treatments. Our first product candidate is designed to target the key enzyme deficiency in advanced heart failure which regulates calcium cycling and contractility in heart muscle cells.

RubrYc Therapeutics

RubrYc Therapeutics is a biotechnology company that integrates chemistry and computation to decode therapeutically significant protein interfaces, revolutionizing the discovery of antibody-based drugs.

Inipharm

At Inipharm, we`re building on novel insights and applying our chemistry expertise to develop therapies for patients with liver disease. Inipharm`s lead program is focused on small-molecules to target the activity of HSD17B13, a highly validated, genetically defined target for multiple severe liver and related diseases.